Sign in
4

Changes in Ownership

Avalo Therapeutics, Inc. Filed Acc 0001062993-22-000731

Options or other derivatives

  • Chief Commercial Officer acquired 400,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Smolinski Stephen · Chief Commercial Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2022-01-04 Grant or award : show line 1 in the form Stock Option (Right to Buy) +400,000 400,000 D
Loading xslF345X03/form4.xml…